Literature DB >> 9526961

Urokinase localization and activity in isolated eosinophils.

C Mabilat-Pragnon1, A Janin, L Michel, A Thomaïdis, Y Legrand, C Soria, H Lu.   

Abstract

Urokinase-type plasminogen activator is implicated in cell invasion and migration. In this study, we provide evidence for the presence of urokinase-type plasminogen activator (3.5 +/- 1.5 ng/mg of cell protein) in isolated peripheral blood eosinophils, in comparison to 6.7 +/- 2.3 ng/mg of protein in neutrophils. Both immunocytochemical and immunogold staining of urokinase-type plasminogen activator on electron microscopy showed its localization in granules of resting cells. Mild stimulation by platelet-activating factor induced a translocation of urokinase-type plasminogen activator from the granules to the cell membrane and a formation of urokinase-type plasminogen activator capping, suggesting a role for urokinase-type plasminogen activator in eosinophil migration. The activation of eosinophils led to the release of factor(s) which, after activation of pro-urokinase-type plasminogen activator, induced an inactivation of generated urokinase-type plasminogen activator. Our results suggest that urokinase-type plasminogen activator is implicated in activated eosinophils invasiveness because the exposure of urokinase-type plasminogen activator is regulated both in space and time.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9526961     DOI: 10.1016/s0049-3848(97)00268-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

1.  Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma.

Authors:  Anne M Brooks; Mary Ellen Bates; Rose F Vrtis; Nizar N Jarjour; Paul J Bertics; Julie B Sedgwick
Journal:  Am J Respir Cell Mol Biol       Date:  2006-05-25       Impact factor: 6.914

2.  Circulating levels of urokinase-type plasminogen activator (uPA) and its soluble receptor (suPAR) in patients with atopic eczema/dermatitis syndrome.

Authors:  Alicja Kasperska-Zajac; Barbara Rogala
Journal:  Inflammation       Date:  2005-04       Impact factor: 4.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.